PHARMACEUTICAL
Untitled Page
Bepreve approved, continued ...
"Patients who experience ocular itching due to allergies want comfortable, quick and long-lasting relief for their eyes," says Gregg Berdy, M.D., an assistant professor of clinical opthalmology at the Washington University School of Medicine.
He calls Bepreve the "first truly new treatment" for the condition that's been approved in a number of years.
On the heels of the FDA's approval of the drug, ISTA is increasing its full-year net product revenue guidance for the company's marketed treatments to $104 million, up from $101 million, according to Anido. Total net revenue for the year – which includes net product revenue and another $2.9 million from its partnership with Otsuka – is rising to $107 million, up from an expected $104 million.
"ISTA will be operating income neutral in 2009, as our increased net revenue will offset the costs associated with launching Bepreve and expanding our sales force," finishes Anido.
ISTA Pharmaceuticals is the fourth-largest branded opthalmic pharmaceutical business in the U.S.
<< PREVIOUS PAGE
Related headlines
Irvine's Spectrum Pharmaceuticals gets FDA nod for cancer therapy
Orange's St. Joseph Hospital debuts revolutionary procedure
'OC METRO Minute,' Sept. 3: Visiogen set to be acquired by Abbot for $400 million
Bepreve approved, continued ...
"Patients who experience ocular itching due to allergies want comfortable, quick and long-lasting relief for their eyes," says Gregg Berdy, M.D., an assistant professor of clinical opthalmology at the Washington University School of Medicine. He calls Bepreve the "first truly new treatment" for the condition that's been approved in a number of years.
On the heels of the FDA's approval of the drug, ISTA is increasing its full-year net product revenue guidance for the company's marketed treatments to $104 million, up from $101 million, according to Anido. Total net revenue for the year – which includes net product revenue and another $2.9 million from its partnership with Otsuka – is rising to $107 million, up from an expected $104 million.
"ISTA will be operating income neutral in 2009, as our increased net revenue will offset the costs associated with launching Bepreve and expanding our sales force," finishes Anido.
ISTA Pharmaceuticals is the fourth-largest branded opthalmic pharmaceutical business in the U.S.
<< PREVIOUS PAGE
Related headlines
Irvine's Spectrum Pharmaceuticals gets FDA nod for cancer therapy
Orange's St. Joseph Hospital debuts revolutionary procedure
'OC METRO Minute,' Sept. 3: Visiogen set to be acquired by Abbot for $400 million
